These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1677 related articles for article (PubMed ID: 8262729)

  • 1. A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.
    Adkins DR; Irvin R; Kuhn J; Boldt DH; Roodman GD; Salzman D; Freytes C; Von Hoff DD; LeMaistre CF
    Invest New Drugs; 1993; 11(2-3):169-79. PubMed ID: 8262729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Adkins DR; Salzman D; Boldt D; Kuhn J; Irvin R; Roodman GD; Lyons R; Smith L; Freytes CO; LeMaistre CF
    J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
    Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
    Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of high-dose diaziquone and autologous bone marrow transplantation: an Illinois Cancer Council study.
    Stiff PJ; McKenzie RS; Potempa LD; Albain K; Koch D; Braud E; Bansal VK; Weidner MK; Lanzotti VJ; Chun HG
    J Clin Oncol; 1991 Aug; 9(8):1487-94. PubMed ID: 2072148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential therapy with dacarbazine and carmustine: a phase I study.
    Mitchell RB; Dolan ME; Janisch L; Vogelzang NJ; Ratain MJ; Schilsky RL
    Cancer Chemother Pharmacol; 1994; 34(6):509-14. PubMed ID: 7923562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue.
    McKeage M; Dady P; Clear M; MacDonald A
    Cancer Chemother Pharmacol; 1992; 29(3):201-6. PubMed ID: 1733552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients.
    Chabot GG; Flaherty LE; Valdivieso M; Baker LH
    Cancer Chemother Pharmacol; 1990; 27(2):157-60. PubMed ID: 2249333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
    Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
    J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of intermittent high-dose dacarbazine.
    Buesa JM; Gracia M; Valle M; Estrada E; Hidalgo OF; Lacave AJ
    Cancer Treat Rep; 1984 Mar; 68(3):499-504. PubMed ID: 6704980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.
    Wilson WH; Jain V; Bryant G; Cowan KH; Carter C; Cottler-Fox M; Goldspiel B; Steinberg SM; Longo DL; Wittes RE
    J Clin Oncol; 1992 Nov; 10(11):1712-22. PubMed ID: 1403054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
    Meisenberg BR; Ross M; Vredenburgh JJ; Jones R; Shpall EJ; Seigler HF; Coniglio DM; Wu K; Peters WP
    J Natl Cancer Inst; 1993 Jul; 85(13):1080-5. PubMed ID: 8515495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose etoposide and marrow transplantation.
    Herzig RH
    Cancer; 1991 Jan; 67(1 Suppl):292-8. PubMed ID: 1984830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
    Ryan DP; Supko JG; Eder JP; Seiden MV; Demetri G; Lynch TJ; Fischman AJ; Davis J; Jimeno J; Clark JW
    Clin Cancer Res; 2001 Feb; 7(2):231-42. PubMed ID: 11234874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
    Attal M; Canal P; Schlaifer D; Chatelut E; Dezeuze A; Huguet F; Payen C; Pris J; Laurent G
    J Clin Oncol; 1994 Jan; 12(1):141-8. PubMed ID: 8270970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.